145 related articles for article (PubMed ID: 19192652)
21. Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin.
Iwahori K; Osaki T; Serada S; Fujimoto M; Suzuki H; Kishi Y; Yokoyama A; Hamada H; Fujii Y; Yamaguchi K; Hirashima T; Matsui K; Tachibana I; Nakamura Y; Kawase I; Naka T
Lung Cancer; 2008 Oct; 62(1):45-54. PubMed ID: 18394747
[TBL] [Abstract][Full Text] [Related]
22. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
[TBL] [Abstract][Full Text] [Related]
23. Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma.
Hollevoet K; Nackaerts K; Thimpont J; Germonpré P; Bosquée L; De Vuyst P; Legrand C; Kellen E; Kishi Y; Delanghe JR; van Meerbeeck JP
Am J Respir Crit Care Med; 2010 Mar; 181(6):620-5. PubMed ID: 20075387
[TBL] [Abstract][Full Text] [Related]
24. Detection of malignant mesothelioma in asbestos-exposed individuals: the potential role of soluble mesothelin-related protein.
Creaney J; Robinson BW
Hematol Oncol Clin North Am; 2005 Dec; 19(6):1025-40, v. PubMed ID: 16325121
[TBL] [Abstract][Full Text] [Related]
25. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer.
Cristaudo A; Foddis R; Vivaldi A; Guglielmi G; Dipalma N; Filiberti R; Neri M; Ceppi M; Paganuzzi M; Ivaldi GP; Mencoboni M; Canessa PA; Ambrosino N; Chella A; Mutti L; Puntoni R
Clin Cancer Res; 2007 Sep; 13(17):5076-81. PubMed ID: 17785560
[TBL] [Abstract][Full Text] [Related]
26. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
[TBL] [Abstract][Full Text] [Related]
27. Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
Park EK; Sandrini A; Yates DH; Creaney J; Robinson BW; Thomas PS; Johnson AR
Am J Respir Crit Care Med; 2008 Oct; 178(8):832-7. PubMed ID: 18583574
[TBL] [Abstract][Full Text] [Related]
28. Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma.
Grigoriu B; Chahine B; Zerimech F; Grégoire M; Balduyck M; Copin MC; Devos P; Lassalle P; Scherpereel A
Clin Biochem; 2009 Jul; 42(10-11):1046-50. PubMed ID: 19302997
[TBL] [Abstract][Full Text] [Related]
29. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
Creaney J; Dick IM; Dare H; Demelker Y; Nowak AK; Musk AW; Robinson BW
Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
[TBL] [Abstract][Full Text] [Related]
30. Blood tests for asbestos-related mesothelioma.
Maeda M; Hino O
Oncology; 2006; 71(1-2):26-31. PubMed ID: 17344668
[TBL] [Abstract][Full Text] [Related]
31. Hyaluronan and N-ERC/mesothelin as key biomarkers in a specific two-step model to predict pleural malignant mesothelioma.
Mundt F; Nilsonne G; Arslan S; Csürös K; Hillerdal G; Yildirim H; Metintas M; Dobra K; Hjerpe A
PLoS One; 2013; 8(8):e72030. PubMed ID: 23991032
[TBL] [Abstract][Full Text] [Related]
32. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
[TBL] [Abstract][Full Text] [Related]
33. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
[TBL] [Abstract][Full Text] [Related]
34. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
35. Serum level of expressed in renal carcinoma (ERC)/ mesothelin in rats with mesothelial proliferative lesions induced by multi-wall carbon nanotube (MWCNT).
Sakamoto Y; Dai N; Hagiwara Y; Satoh K; Ohashi N; Fukamachi K; Tsuda H; Hirose A; Nishimura T; Hino O; Ogata A
J Toxicol Sci; 2010 Apr; 35(2):265-70. PubMed ID: 20371980
[TBL] [Abstract][Full Text] [Related]
36. Establishment of a novel specific ELISA system for rat N- and C-ERC/mesothelin. Rat ERC/mesothelin in the body fluids of mice bearing mesothelioma.
Hagiwara Y; Hamada Y; Kuwahara M; Maeda M; Segawa T; Ishikawa K; Hino O
Cancer Sci; 2008 Apr; 99(4):666-70. PubMed ID: 18294289
[TBL] [Abstract][Full Text] [Related]
37. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
Boudville N; Paul R; Robinson BW; Creaney J
Lung Cancer; 2011 Sep; 73(3):320-4. PubMed ID: 21333373
[TBL] [Abstract][Full Text] [Related]
38. Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
Grigoriu BD; Chahine B; Vachani A; Gey T; Conti M; Sterman DH; Marchandise G; Porte H; Albelda SM; Scherpereel A
Am J Respir Crit Care Med; 2009 May; 179(10):950-4. PubMed ID: 19201924
[TBL] [Abstract][Full Text] [Related]
39. A prospective study to investigate the role of serial serum mesothelin in monitoring mesothelioma.
de Fonseka D; Arnold DT; Stadon L; Morley A; Keenan E; Darby M; Armstrong L; Virgo P; Maskell NA
BMC Cancer; 2018 Feb; 18(1):199. PubMed ID: 29454314
[TBL] [Abstract][Full Text] [Related]
40. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
Creaney J; Yeoman D; Musk AW; de Klerk N; Skates SJ; Robinson BW
Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
